Sarepta Therapeutics Inc. (NASDAQ:SRPT) SVP David T. Howton sold 9,304 shares of the firm’s stock in a transaction dated Monday, September 19th. The shares were sold at an average price of $50.00, for a total transaction of $465,200.00. Following the completion of the sale, the senior vice president now owns 11,168 shares of the company’s stock, valued at approximately $558,400. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.
Shares of Sarepta Therapeutics Inc. (NASDAQ:SRPT) opened at 57.83 on Monday. The stock’s 50 day moving average is $30.90 and its 200 day moving average is $22.21. Sarepta Therapeutics Inc. has a 52 week low of $8.00 and a 52 week high of $61.60. The stock’s market capitalization is $2.77 billion.
Sarepta Therapeutics (NASDAQ:SRPT) last posted its quarterly earnings data on Tuesday, July 19th. The company reported ($1.35) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.19) by $0.16. During the same quarter last year, the company posted ($0.87) EPS. Analysts anticipate that Sarepta Therapeutics Inc. will post ($4.17) EPS for the current fiscal year.
Several hedge funds and other institutional investors have recently bought and sold shares of the stock. BlackRock Fund Advisors boosted its position in Sarepta Therapeutics by 2.2% in the first quarter. BlackRock Fund Advisors now owns 1,661,818 shares of the company’s stock valued at $32,439,000 after buying an additional 36,371 shares during the period. State Street Corp raised its stake in Sarepta Therapeutics by 54.0% in the first quarter. State Street Corp now owns 2,467,376 shares of the company’s stock valued at $48,168,000 after buying an additional 865,658 shares in the last quarter. Commonwealth Equity Services Inc acquired a new stake in Sarepta Therapeutics during the second quarter valued at approximately $302,000. National Planning Corp raised its stake in Sarepta Therapeutics by 2.1% in the first quarter. National Planning Corp now owns 13,678 shares of the company’s stock valued at $242,000 after buying an additional 275 shares in the last quarter. Finally, TIAA CREF Investment Management LLC raised its stake in Sarepta Therapeutics by 5.5% in the first quarter. TIAA CREF Investment Management LLC now owns 216,707 shares of the company’s stock valued at $4,230,000 after buying an additional 11,334 shares in the last quarter. Institutional investors and hedge funds own 72.09% of the company’s stock.
A number of equities research analysts recently commented on the stock. Oppenheimer Holdings Inc. restated a “buy” rating and issued a $60.00 price objective on shares of Sarepta Therapeutics in a research report on Sunday, July 17th. Piper Jaffray Cos. restated a “sell” rating and issued a $6.00 price objective on shares of Sarepta Therapeutics in a research report on Saturday, June 4th. Vetr downgraded shares of Sarepta Therapeutics from a “buy” rating to a “strong sell” rating and set a $17.28 price objective for the company. in a research report on Wednesday, June 8th. JMP Securities reiterated an “underperform” rating and set a $10.00 price target on shares of Sarepta Therapeutics in a research report on Thursday, September 15th. Finally, Cowen and Company reiterated a “hold” rating on shares of Sarepta Therapeutics in a research report on Tuesday, June 7th. One investment analyst has rated the stock with a sell rating, five have given a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average target price of $48.70.
About Sarepta Therapeutics
Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery and development of ribonucleic acid (RNA)-targeted therapeutics for the treatment of rare, infectious and other diseases. The Company operates in one segment: the development of pharmaceutical products on its own behalf or in collaboration with others.
Receive News & Ratings for Sarepta Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.